BioPharma Resources

Drug Trial Radar · NCT06424288

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 6,712 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,712

Planned (sponsor's estimate)

Start

Jun 17, 2024

Primary completion

May 22, 2028

Study completion May 22, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Conditions

  • Heart Failure

Interventions

  • vicadrostatDrug

    vicadrostat

  • empagliflozinDrug

    empagliflozin

  • placeboDrug

    placebo matching vicadrostat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first event of Cardiovascular (CV) death, hospitalisation for heart failure (HHF) or urgent heart failure (HF) visitTime frame: up to 42 months

Locations

672 sites in 30 countries. Site status is shown where the registry gives one.

  • Diagnostic and Medical Clinic

    Mobile, Alabama · Recruiting

  • Mobile Heart Specialists, PC

    Mobile, Alabama · Recruiting

  • Velocity Clinical Research-Chula Vista

    Chula Vista, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • North America Research Institute

    San Dimas, California · Recruiting

  • Amicis Research Center - Valencia

    Santa Clarita, California · Recruiting

  • Orange County Research Center

    Tustin, California · Recruiting

  • Bridgeport Hospital

    Bridgeport, Connecticut · Recruiting

  • Flourish Research

    Boca Raton, Florida · Recruiting

  • Bay Area Cardiology

    Brandon, Florida · Recruiting

  • Clearwater Cardiovascular and Interventional Consultants

    Clearwater, Florida · Recruiting

  • Cardiology Associates Research Co.

    Daytona Beach, Florida · Recruiting

  • Malcom Randall VA Medical Center

    Gainesville, Florida · Recruiting

  • Velocity Clinical Research-Hallandale Beach-67888

    Hallandale, Florida · Recruiting

  • University of Florida Health Jacksonville

    Jacksonville, Florida · Recruiting

  • East Coast Institute for Research, LLC - Jacksonville

    Jacksonville, Florida · Recruiting

  • First Coast Cardiovascular Institute

    Jacksonville, Florida · Recruiting

  • Clearwater Cardiovascular Consultants-Largo-69917

    Largo, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Sacred Heart Medical Specialty Group

    Miramar Beach, Florida · Recruiting

  • Advanced Research for Health Improvement, LLC

    Naples, Florida · Not yet recruiting

  • Southwest Florida Research, LLC

    Naples, Florida · Recruiting

  • Ocala Cardiovascular Research

    Ocala, Florida · Recruiting

  • Ocala Research Institute, Inc

    Ocala, Florida · Recruiting

  • Charlotte Cardiovascular Institute, PA

    Port Charlotte, Florida · Recruiting

  • East Coast Institute for Research, LLC-Saint Augustine-63032

    Saint Augustine, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Recruiting

  • Cardiology Partners Clinical Research Institute

    Wellington, Florida · Recruiting

  • Cozy Research LLC

    Wesley Chapel, Florida · Recruiting

  • Flourish Research

    Winter Park, Florida · Recruiting

  • Atlanta Clinical Research Centers

    Atlanta, Georgia · Recruiting

  • Columbus Regional Research Institute

    Columbus, Georgia · Recruiting

  • NSC Research Inc

    Johns Creek, Georgia · Recruiting

  • Kootenai Medical Center

    Coeur d'Alene, Idaho · Recruiting

  • Northwest Heart Clinical Research, LLC

    Arlington Heights, Illinois · Recruiting

  • Illinois Masonic Hospital

    Chicago, Illinois · Recruiting

  • Chicago Medical Research

    Hazel Crest, Illinois · Recruiting

  • Clinical Investigation Specialists, Inc.-Libertyville-69941

    Libertyville, Illinois · Recruiting

  • AMR Park Ridge

    Park Ridge, Illinois · Recruiting

  • Midwest Cardiovascular Research and Education Foundation

    Elkhart, Indiana · Recruiting

Showing 40 of 672 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.